

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Fabien M. Decaillot	POSITION TITLE Research Associate
eRA COMMONS USER NAME	

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Université Pierre et Marie Curie, Paris, France	B.S	1994	
Université Louis Pasteur de Strasbourg, France	M.S.	1996	Biochemistry
Université Louis Pasteur de Strasbourg, France	Ph.D	2002	Pharmacology
Mount Sinai School of Medicine, New York		2003- 2008	Neuropharmacology

Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch.

**Research and Professional Experience**

Training at Dept. D'Ingenierie et d'Etude des Proteins, Commisariat a l'Energie Atomique, Paris	1998
Scientist at AstraZeneca, Montreal, Canada	1999-2000
Postdoctoral fellow with Dr. Lakshmi Devi, Mount Sinai School of Medicine	2003-2008
Postdoctoral Associate with Dr. Thomas P. Sakmar, Rockefeller University	2008- present

**Honors and Awards**

MENRT Government Fellowship	1998-2001
ARC Fellowship	2001-2002

**Publications**

Gupta A, Rozenfeld R, Gomes I, Raehal KM, Decaillot FM, Bohn LM and Devi LA.  
Post-activation mediated changes in opioid receptors detected by N-terminal antibodies.  
J Biol Chem. 2008 Feb 6; [Epub ahead of print]

Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES and Devi LA. Conformation state-sensitive antibodies to G-protein-coupled receptors. J. Biol. Chem. 2007 Feb 23;282(8):5116-24.

Gupta A., Decaillot F.M. and Devi L.A. Targeting opioid receptors heterodimers: Strategies for screening and drug development. A.A.P.S. Journal (2006), 8(1):E153-9.

Decaillot, F.M., Che, F-Y., Fricker, L.D. and Devi, L.A. Peptidomics of Cpe<sup>fat/fat</sup> mouse hypothalamus and striatum: Effect of chronic morphine administration. J. Mol. Neurosci. (2006), 28(3):277-84.

Tryoen-Toth P, Decaillot FM, Filliol D, Befort K, Lazarus LH, Schiller PW, Schmidhammer H, Kieffer BL.  
Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid

Principal Investigator/Program Director (Last, First, Middle): Volkman, B. / Rockefeller University

receptors. *J. Pharmacol. Exp. Ther.* (2005), 1:410-21.

Decaillot FM, Befort K, Filliol D, Yue S, Walker P, Kieffer BL. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. *Nature, Struct. Biol.* (2003) 10:629-36, 2003

Décaillot F.M. and Kieffer B. L. *In vitro* and *in vivo* mutagenesis: insights into delta receptor structure and Function. *In: The delta receptor* (Chang K.-J., Porreca F. and Woods J.H., eds) Marcel Dekker, Inc. 2003

Décaillot F.M., Befort K., Filliol D., Yue S.Y., Walker P. and Kieffer B.L., Delta Opioid Receptor activation by random mutagenesis. Oral presentation at the Society for Neuroscience Conference in Orlando, Florida, 2002

Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. *J. Biol. Chem.* (2001) 276:3130-7.